Home
NewsNewsWith ART Fertility Clinics now part of its network, IVI RMA Global has created a Middle East operating region to meet growing fertility needs. The integration boosts treatment capacity, scientific output, and care consistency across the UAE and Saudi Arabia as demographic pressures shape demand for assisted reproduction
IVI RMA Global has named the Middle East as its newest operating region after acquiring ART Fertility Clinics, a move that marks an important step in the IVI RMA Global expansion into fast-growing reproductive markets. The integration covers ART Fertility’s established operations in the UAE and its planned entry into Saudi Arabia, extending the company’s network beyond North America, Italy, Northern Europe, Iberia, Latam, and Czechia. Led by CEO Suresh Soni and Medical Director Dr. Human M. Fatemi, the move positions the combined platform to serve tens of thousands of patients across the region.
The expansion comes as the Middle East faces declining fertility rates, with World Bank data showing the UAE at 1.2 births per woman and continued declines in Saudi Arabia. Dr. Fatemi said, “Across the Middle East, there is a growing awareness of the importance of addressing fertility challenges directly, and we are seeing more individuals and couples seeking advanced solutions every day,” adding that ART Fertility’s integration will accelerate scientific progress and raise care standards. The acquisition strengthens the IVI RMA Global expansion strategy by bringing more than 300 clinicians, embryologists, and geneticists into its network, supported by proprietary research and protocols that have delivered pregnancy rates as high as 71% across multiple age groups.
Soni noted, “The entire ART Fertility team is excited about this combination of two leaders in global fertility meeting the fertility challenge in the Middle East,” highlighting opportunities to deepen clinical value and research output. ART Fertility’s scientific footprint stretches across major R&D investments, more than 268 peer-reviewed papers, 35 ongoing studies, and 11 conferences. Together, these efforts have helped cement its role as a reference point in reproductive medicine. These capabilities align with the broader IVI RMA Global expansion effort aimed at advancing fertility science and strengthening clinical practice across the region.
Javier Sánchez Prieto, CEO of IVI RMA Global, said, “We are always looking for quality organizations that meet our high standards and whose own success can strengthen our work,” emphasizing the expectation that demand for fertility care in the Middle East will continue to grow. The acquisition places IVI RMA in a strong position to lead scientific and clinical advancements throughout the region.
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
